Literature DB >> 22535658

Myeloma as a model for the process of metastasis: implications for therapy.

Irene M Ghobrial1.   

Abstract

Multiple myeloma (MM) is a plasma cell dyscrasia characterized by the presence of multiple myelomatous "omas" throughout the skeleton, indicating that there is continuous trafficking of tumor cells to multiple areas in the bone marrow niches. MM may therefore represent one of the best models to study cell trafficking or cell metastasis. The process of cell metastasis is described as a multistep process, the invasion-metastasis cascade. This involves cell invasion, intravasation into nearby blood vessels, passage into the circulation, followed by homing into predetermined distant tissues, the formation of new foci of micrometastases, and finally the growth of micrometastasis into macroscopic tumors. This review discusses the significant advances that have been discovered in the complex process of invasion-metastasis in epithelial carcinomas and cell trafficking in hematopoietic stem cells and how this process relates to progression in MM. This progression is mediated by clonal intrinsic factors that mediate tumor invasiveness as well as factors present in the tumor microenvironment that are permissive to oncogenic proliferation. Therapeutic agents that target the different steps of cell dissemination and progression are discussed. Despite the significant advances in the treatment of MM, better therapeutic agents that target this metastatic cascade are urgently needed.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22535658      PMCID: PMC3390959          DOI: 10.1182/blood-2012-01-379024

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  149 in total

1.  Cell adhesion mediated drug resistance (CAM-DR): role of integrins and resistance to apoptosis in human myeloma cell lines.

Authors:  J S Damiano; A E Cress; L A Hazlehurst; A A Shtil; W S Dalton
Journal:  Blood       Date:  1999-03-01       Impact factor: 22.113

2.  Multiple myeloma; lesions of the extra-osseous hematopoietic system.

Authors:  J CHURG; A J GORDON
Journal:  Am J Clin Pathol       Date:  1950-10       Impact factor: 2.493

3.  Accumulation of major histocompatibility complex class II molecules in mast cell secretory granules and their release upon degranulation.

Authors:  G Raposo; D Tenza; S Mecheri; R Peronet; C Bonnerot; C Desaymard
Journal:  Mol Biol Cell       Date:  1997-12       Impact factor: 4.138

4.  Targeted disruption of Cbfa1 results in a complete lack of bone formation owing to maturational arrest of osteoblasts.

Authors:  T Komori; H Yagi; S Nomura; A Yamaguchi; K Sasaki; K Deguchi; Y Shimizu; R T Bronson; Y H Gao; M Inada; M Sato; R Okamoto; Y Kitamura; S Yoshiki; T Kishimoto
Journal:  Cell       Date:  1997-05-30       Impact factor: 41.582

5.  IgD monoclonal gammopathy with long-term follow-up.

Authors:  J Bladé; R A Kyle
Journal:  Br J Haematol       Date:  1994-10       Impact factor: 6.998

6.  CXCR4 regulates growth of both primary and metastatic breast cancer.

Authors:  Matthew C P Smith; Kathryn E Luker; Joel R Garbow; Julie L Prior; Erin Jackson; David Piwnica-Worms; Gary D Luker
Journal:  Cancer Res       Date:  2004-12-01       Impact factor: 12.701

7.  Adhesion of human myeloma-derived cell lines to bone marrow stromal cells stimulates interleukin-6 secretion.

Authors:  H Uchiyama; B A Barut; A F Mohrbacher; D Chauhan; K C Anderson
Journal:  Blood       Date:  1993-12-15       Impact factor: 22.113

8.  Primary plasma cell leukemia: clinical, immunophenotypic, DNA ploidy, and cytogenetic characteristics.

Authors:  R García-Sanz; A Orfão; M González; M D Tabernero; J Bladé; M J Moro; J Fernández-Calvo; M A Sanz; J A Pérez-Simón; A Rasillo; J F Miguel
Journal:  Blood       Date:  1999-02-01       Impact factor: 22.113

9.  Presenting features and prognosis in 72 patients with multiple myeloma who were younger than 40 years.

Authors:  J Bladé; R A Kyle; P R Greipp
Journal:  Br J Haematol       Date:  1996-05       Impact factor: 6.998

10.  B lymphocytes secrete antigen-presenting vesicles.

Authors:  G Raposo; H W Nijman; W Stoorvogel; R Liejendekker; C V Harding; C J Melief; H J Geuze
Journal:  J Exp Med       Date:  1996-03-01       Impact factor: 14.307

View more
  77 in total

1.  In vivo adhesion of malignant B cells to bone marrow microvasculature is regulated by α4β1 cytoplasmic-binding proteins.

Authors:  M Martínez-Moreno; M Leiva; N Aguilera-Montilla; S Sevilla-Movilla; S Isern de Val; N Arellano-Sánchez; N C Gutiérrez; R Maldonado; J Martínez-López; I Buño; J A García-Marco; P Sánchez-Mateos; A Hidalgo; A García-Pardo; J Teixidó
Journal:  Leukemia       Date:  2015-12-10       Impact factor: 11.528

2.  Bone marrow fibroblasts parallel multiple myeloma progression in patients and mice: in vitro and in vivo studies.

Authors:  M A Frassanito; L Rao; M Moschetta; R Ria; L Di Marzo; A De Luisi; V Racanelli; I Catacchio; S Berardi; A Basile; E Menu; S Ruggieri; B Nico; D Ribatti; R Fumarulo; F Dammacco; K Vanderkerken; A Vacca
Journal:  Leukemia       Date:  2013-09-02       Impact factor: 11.528

3.  The sialyltransferase ST3GAL6 influences homing and survival in multiple myeloma.

Authors:  Siobhan V Glavey; Salomon Manier; Alessandro Natoni; Antonio Sacco; Michele Moschetta; Michaela R Reagan; Laura S Murillo; Ilyas Sahin; Ping Wu; Yuji Mishima; Yu Zhang; Wenjing Zhang; Yong Zhang; Gareth Morgan; Lokesh Joshi; Aldo M Roccaro; Irene M Ghobrial; Michael E O'Dwyer
Journal:  Blood       Date:  2014-07-24       Impact factor: 22.113

Review 4.  MGUS to myeloma: a mysterious gammopathy of underexplored significance.

Authors:  Madhav V Dhodapkar
Journal:  Blood       Date:  2016-10-13       Impact factor: 22.113

5.  Extramedullary involvement in multiple myeloma.

Authors:  Joan Bladé; Carlos Fernández de Larrea; Laura Rosiñol
Journal:  Haematologica       Date:  2012-11       Impact factor: 9.941

6.  Targeting of stromal versican by miR-144/199 inhibits multiple myeloma by downregulating FAK/STAT3 signalling.

Authors:  Nidhi Gupta; Raman Kumar; Tulika Seth; Bhavuk Garg; Alpana Sharma
Journal:  RNA Biol       Date:  2019-09-29       Impact factor: 4.652

7.  Blood monitoring of circulating tumor plasma cells by next generation flow in multiple myeloma after therapy.

Authors:  Luzalba Sanoja-Flores; Juan Flores-Montero; Noemi Puig; Teresa Contreras-Sanfeliciano; Roberia Pontes; Alba Corral-Mateos; Omar García-Sánchez; María Díez-Campelo; Roberto José Pessoa de Magalhães; Luis García-Martín; José María Alonso-Alonso; Aranzazú García-Mateo; Carlos Aguilar-Franco; Jorge Labrador; Abelardo Barez-García; Angelo Maiolino; Bruno Paiva; Jesús San Miguel; Elaine Sobral da Costa; Marcos González; María Victoria Mateos; Brian Durie; Jacques J M van Dongen; Alberto Orfao
Journal:  Blood       Date:  2019-12-12       Impact factor: 22.113

8.  Twist-1 is upregulated by NSD2 and contributes to tumour dissemination and an epithelial-mesenchymal transition-like gene expression signature in t(4;14)-positive multiple myeloma.

Authors:  Chee Man Cheong; Krzysztof M Mrozik; Duncan R Hewett; Elyse Bell; Vasilios Panagopoulos; Jacqueline E Noll; Jonathan D Licht; Stan Gronthos; Andrew C W Zannettino; Kate Vandyke
Journal:  Cancer Lett       Date:  2020-01-31       Impact factor: 8.679

9.  Quantification of clonal circulating plasma cells in newly diagnosed multiple myeloma: implications for redefining high-risk myeloma.

Authors:  W I Gonsalves; S V Rajkumar; V Gupta; W G Morice; M M Timm; P P Singh; A Dispenzieri; F K Buadi; M Q Lacy; P Kapoor; M A Gertz; S K Kumar
Journal:  Leukemia       Date:  2014-03-12       Impact factor: 11.528

Review 10.  Targeted therapy in rare cancers--adopting the orphans.

Authors:  Javier Munoz; Razelle Kurzrock
Journal:  Nat Rev Clin Oncol       Date:  2012-09-11       Impact factor: 66.675

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.